Amanote Research
Register
Sign In
Sintilimab for Relapsed/Refractory (R/R) Extranodal Nk/T Cell Lymphoma (Enktl): A Multicenter, Single-Arm, Phase 2 Trial (Orient-4)
Hematological Oncology
- United Kingdom
doi 10.1002/hon.66_2629
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2019
Authors
R. Tao
L. Fan
Y. Song
Y. Hu
W. Zhang
Y. Wang
L. Xu
H. Zhou
J. Li
Publisher
Wiley
Related search
Treatment of Extranodal Nk/T-Cell Lymphoma, Nasal Type (Enktl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial
The Lancet Oncology
Oncology
LMP1 and LMP2A Are Potential Prognostic Markers of Extranodal NK/T-cell Lymphoma, Nasal Type (ENKTL)
Diagnostic Pathology
Forensic Medicine
Medicine
Pathology
Histology
Extranodal NK/T Cell Lymphoma, Nasal Type
Trends in General Practice
A Phase 1 Study of Pralatrexate Plus Romidepsin Reveals Marked Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
